1. Liposomal Doxorubicin Plus Radiofrequency Ablation for Complete Necrosis of a Hepatocellular Carcinoma
- Author
-
S. K. Libutti, Bradford J. Wood, and Cheng William Hong
- Subjects
liposomes ,medicine.medical_specialty ,Necrosis ,Combination therapy ,Radiofrequency ablation ,medicine.medical_treatment ,Case Report ,Liver transplantation ,ablation ,doxorubicin ,law.invention ,law ,Medicine ,Doxorubicin ,rfa ,business.industry ,Standard treatment ,hepatocellular carcinoma ,Ablation ,medicine.disease ,digestive system diseases ,Surgery ,surgical procedures, operative ,Hepatocellular carcinoma ,Radiology ,medicine.symptom ,business ,therapeutics ,medicine.drug - Abstract
Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, RFA for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during RFA is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a HCC in a patient who underwent liver transplantation 79 days later.
- Published
- 2013
- Full Text
- View/download PDF